Background: In 2002, the World Health Organization (WHO) launched a regional microbiology external 28 quality assessment (EQA) programme for national public health laboratories in the African region, initially 29 targeting priority epidemic-prone bacterial diseases, and later including other common bacterial pathogens.
Introduction

51
Antibiotic resistance is a worldwide health threat: at least 700 000 people die annually due to antibiotic-resistant 52 pathogens, and this figure is projected to reach 10 million by 2050. 1 It is a severe and growing global health 53 security risk, which needs to be prioritised at country, regional and international levels. Globally, a projected 50% of antibiotic agents can be acquired without a prescription, predominantly on the 61 informal market in some parts of Africa, South America and Asia. 1 In the World Health Organization (WHO) 62 African Region, many countries have developed regulations that restrict the access to antibiotics without a 63 prescription; however, these regulations are not enforced in three-quarters of African Region nations. 2 In 2014, 64 a WHO report showed that 19 European countries had unrestricted access to antibiotics, 2,3 which supports 65 evidence for the overuse of antibiotics and the increasing threat of resistant pathogens. For credible and reliable AMR surveillance, it is essential that countries support laboratory systems capable of 74 providing good quality data in a standardised format. Arising from the Integrated Disease Surveillance and 75 Response strategy, the WHO Regional Office for Africa (AFRO) advocated the use of standard laboratory diagnostic methods for priority diseases, and the implementation of quality assurance in clinical diagnostic 77 bacteriology.
79
In July 2002, WHO launched a regional microbiology external quality assessment (EQA) programme for 80 national public health and other laboratories in the African Region, initially targeting priority epidemic-prone 81 bacterial diseases, and later including other bacterial pathogens, 4 predominantly common causes of meningitis, The grading scheme for bacterial species identification assessed responses based on a clinical impact on an 120 imaginary patient. The most correct answer was awarded a score of 4/4; an answer that was not completely 121 correct, with no or little clinical impact, scored 3/4; a score of 1/4 was awarded for an answer that could lead to 122 a minor diagnosis or treatment error, and a zero score was assigned for a major diagnosis or treatment error. 
Ethical considerations 150
As no human or animal material was used for this programme and the external quality assessment programme 151 followed ISO/IEC 17043 guidelines, no ethical permission was required. 
Results
155
For organism identification, 1662/2184 (76%) of responses over 41 surveys were scored as acceptable ( Laboratory performance for identification of enterococci and streptococci and for AST were very poor. Possible 211 reasons for this include the use of inappropriate, expired or poorly quality-controlled media and reagents, 212 including antibiotic discs, and a lack of incubation temperature control. Based on ongoing poor performance for 213 identification and AST, we recorded a lack of quality management systems in the laboratories for dealing with 214 non-conformance. This suggests a deficiency in laboratory leadership to implement regular corrective actions, 215 as reflected by laboratories repeating the same mistakes across surveys. It is important to note that laboratories 216 rarely have support from clinical microbiologists, based on responses received from our evaluation forms.
218
One third of participants were persistent non-responders, which is consistent with the previous study described 219 by our group. 5 Following RAG meeting discussions, some laboratories were removed from the programme after Implementation of a sustainable quality management system that qualifies for a recognised accreditation 236 scheme would be the optimal solution and would provide confidence in the quality of laboratory results.
237
Laboratory assessments should emphasise implementation of diagnostic stewardship programmes, which 238 improve the utilisation of microbiological tests and results at the clinician level.
240
In a stepwise approach for implementation of AMR surveillance in Africa, 11, 12, 13, 14 the emphasis is on the 241 development of laboratory capability to perform surveillance activities. To apply these activities, commitment is This report indicates an urgent need for clinical bacteriology laboratory capacity building on the continent, as 260 AMR was only recently recognised as a critical problem. The Freetown Declaration was launched in 2015 to 261 establish public health laboratory networks for AMR surveillance in Africa, and AMR was also highlighted in 262 the regional strategy for health security and emergencies adopted by member states during the regional WHO 263 committee meeting in 2016. 13, 14 264 265 Acknowledgements 266 We wish to thank all laboratory staff members, Husna Ismail for statistical analysis, Karen Keddy and Arvinda 267 Sooka, and other members of RAG for their continuous contributions to the programme. We also thank the 268 teams in participating laboratories.
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